Fetroja® – Administration via a Midline Catheter

SHIONOGI

This medical response contains information in addition to that provided in the Fetroja® (cefiderocol) for injection, for intravenous use Full Prescribing Information approved by the U.S. Food and Drug Administration (FDA). Shionogi does not recommend the use of Fetroja in any manner other than as described in the Full Prescribing Information. **Please read the attached Fetroja Full Prescribing Information**.

Summary



- There is **no recommendation** for the administration of cefiderocol through a specific type of venous access or catheter (eg, midline catheter)
- **Clinical studies** comparing the administration of cefiderocol through various types of venous access or catheters (eg, midline catheter) **have not been conducted**

Fetroja® – Administration via a Midline Catheter

SHIONOGI

This medical response contains information in addition to that provided in the Fetroja® (cefiderocol) for injection, for intravenous use Full Prescribing Information approved by the U.S. Food and Drug Administration (FDA). Shionogi does not recommend the use of Fetroja in any manner other than as described in the Full Prescribing Information. **Please read the attached Fetroja Full Prescribing Information**.

Relevant Prescribing Information

Fetroja® is indicated in patients 18 years of age or older for the treatment of:[2]

- Complicated urinary tract infections (cUTIs), including pyelonephritis caused by the following susceptible Gram-negative microorganisms:
  - *Escherichia coli*
  - *Klebsiella pneumoniae*
  - *Proteus mirabilis*
  - *Pseudomonas aeruginosa*
  - *Enterobacter cloacae* complex
- Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by the following susceptible Gram-negative microorganisms:
  - *Acinetobacter baumannii* complex
  - *Escherichia coli*
  - *Enterobacter cloacae* complex
  - *Klebsiella pneumoniae*
  - *Pseudomonas aeruginosa*
  - *Serratia marcescens*

Fetroja is contraindicated in:[2]

- Patients with a known history of severe hypersensitivity to cefiderocol or other beta-lactam antibacterial drugs, or any other component of **Fetroja**

Please read the attached **Fetroja Full Prescribing Information**

Fetroja® – Administration via a Midline Catheter

This medical response contains information in addition to that provided in the Fetroja® (cefiderocol) for injection, for intravenous use Full Prescribing Information approved by the U.S. Food and Drug Administration (FDA). Shionogi does not recommend the use of Fetroja in any manner other than as described in the Full Prescribing Information. **Please read the attached Fetroja Full Prescribing Information**.

Literature Search

Dec 2025

As of December 2025, a computerized search of the published medical literature using internal and external databases (ie, Medline® and Embase®) has failed to identify any additional relevant references regarding cefiderocol administration through a midline catheter.

Please keep in mind that medical literature databases, while considered a major source of biomedical information, are selective in their sources, and the information derived from it should not be considered all-inclusive.

Fetroja® – Administration via a Midline Catheter

SHIONOGI

This medical response contains information in addition to that provided in the Fetroja® (cefiderocol) for injection, for intravenous use Full Prescribing Information approved by the U.S. Food and Drug Administration (FDA). Shionogi does not recommend the use of Fetroja in any manner other than as described in the Full Prescribing Information. **Please read the attached Fetroja Full Prescribing Information**.

Abbreviations

CLcr	creatinine clearance	HABP	hospital-acquired bacterial pneumonia
CRRT	continuous renal replacement therapy	HD	hemodialysis
cUTIs	complicated urinary tract infections	IV	intravenous
FDA	US Food and Drug Administration	VABP	ventilator-associated bacterial pneumonia

References

1. Fetroja® (cefiderocol) for injection, for intravenous use [Prescribing Information]. Shionogi Inc.

Enclosure

Fetroja® (cefiderocol) for injection, for intravenous use [Prescribing Information]. Shionogi Inc.